Earendil Labs begins phase 2a trial of ulcerative colitis therapy
April 03, 2026 | 10:16
The biotechnology company administered its HXN-1001 antibody to the initial participant in mid-stage testing for the inflammatory bowel disease.
Earendil Labs, Sanofi Ink Global License Deal for Next-Gen Autoimmune Therapies
April 18, 2025 | 16:23
Earendil Labs and Sanofi today announced that they have entered into a license agreement for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases.
Latest News
Mobile Version